Interv Akut Kardiol. 2007;6(2):61-64

Solubilný ligand CD40 a akútne koronárne syndrómy

Róbert ©evčík1, Jan Vojáček1,2, Josef Bis1, Jaroslav Duąek1, Josef ©»ásek2, Radek Pudil1
1 I. interní klinika Fakultní nemocnice v Hradci Králové
2 Kardiocentrum dospělých, oddělení invazivní kardiologie interní kliniky 2. LF UK a FN Motol, Praha

Súčasný výskum sa sústredí na molekuly, ktorými by sme mohli detekova» skorąie ątádiá akútnych koronárnych syndrómov ako sme schopní s troponínmi. Solubilný CD40L predstavuje unikátne spojenie medzi trombózou a lokálnym zápalovým procesom. Podµa klinických údajov sú jeho zvýąené hladiny spojené s vysokým rizikom smrtelného infarktu myokardu, chronického srdcového zlyhania alebo rekurentného infarktu u pacientov s akútnym koronárnym syndrómom. Mohol by odhali» pacientov, ktorí by profitovali z terapie IIb/IIIa antagonistami a stratifikova» riziko trombózy pred plánovanou implantáciou stentu. K definitívnemu stanovisku sú potrebné ďaląie ątúdie.

Keywords: solubilný ligand CD40, akutné koronárne syndrómy, kardiomarkery

Published: June 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©evčík R, Vojáček J, Bis J, Duąek J, ©»ásek J, Pudil R. Solubilný ligand CD40 a akútne koronárne syndrómy. Interv Akut Kardiol. 2007;6(2):61-64.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Henn V, Slupsky JR, Grafe M et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591-594. Go to original source... Go to PubMed...
    2. Hollenbaugh D, Grosmaire LS, Kullas CD et al. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity. EMBO J 1992;11:4313-4321. Go to original source... Go to PubMed...
    3. Grewal IS, Flavell RA. The CD40 ligand. At the center of the immune universe? Immunol Res 1997;16:59-70. Go to original source... Go to PubMed...
    4. May AE, Kalsch T, Massberg S et al. Engagement of glycoprotein IIb/IIIa (alpha(IIb)beta3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells. Circulation 2002;106:2111-2117. Go to original source... Go to PubMed...
    5. Buhlmann JE, Noelle RJ. Therapeutic potential for blockade of the CD40 ligand, gp39. J Clin Immunol 1996;16:83-89. Go to original source... Go to PubMed...
    6. Aukrust P, Muller F, Ueland T et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999;100:614-620. Go to original source... Go to PubMed...
    7. Garlichs CD, Eskafi S, Raaz D et al. Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart 2001;86:649-655. Go to original source... Go to PubMed...
    8. Lee Y, Lee WH, Lee SC et al. CD40L activation in circulating platelets in patients with acute coronary syndrome. Cardiology 1999;92:11-16. Go to original source... Go to PubMed...
    9. Peng DQ, Zhao SP, Li YF et al. Elevated soluble CD40 ligand is related to the endothelial adhesion molecules in patients with acute coronary syndrome. Clin Chim Acta 2002;319:19-26. Go to original source... Go to PubMed...
    10. Heeschen C, Dimmeler S, Hamm CW et al. Soluble CD40 ligand in acute coronary syndromes. Circulation,2003;107:2109-2114. Go to original source... Go to PubMed...
    11. Yan J, Wu Z, Huang Z et al. Clinical implications of increased expression of CD40L in patients with acute coronary syndromes. Chin Med J 2002;115:491-493.
    12. Freedman JE, Loscalzo J: Platelet-monocyte aggregates: bridging thrombosis and in flammation. Circulation.2002;105(18):2130-2. Go to original source... Go to PubMed...
    13. Andre P, Prasad KS, Denis CV et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med. 2002;8: 247-252. Go to original source... Go to PubMed...
    14. Chai H, Yan S, Wang H et al. CD40 ligand increases expression of its receptor CD40 in human coronary artery endothelial cells. Surgery 2006 Aug;140(2):236-42. Go to original source... Go to PubMed...
    15. Schönbeck U, Varo N, Libby P et al. Soluble CD40L and cardiovascular risk in women. Circulation. 2001;104:2266-2268. Go to original source... Go to PubMed...
    16. Freedman JE. CD40 ligand-assessing risk instead of damage? N Engl J Med. 2003; 348:1163-1165. Go to original source... Go to PubMed...
    17. Ridker PM, Hennekens CH, Buring JE et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843. Go to original source... Go to PubMed...
    18. Furman MI, Krueger LA, Linden MD. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol. 2004;43(12):2326-8. Go to original source... Go to PubMed...
    19. Chu CS, Lee KT, Lee MY et al. Effects of atorvastatin and atorvastatin withdrawal on soluble CD40L and adipocytokines in patients with hypercholesterolaemia. Acta Cardiol. 2006;61:263-9. Go to original source... Go to PubMed...
    20. Varo N, de Lemos JA, Libby P et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation. 2003;108:1049-52. Go to original source... Go to PubMed...
    21. Turker S, Guneri S, Akdeniz B et al. Usefulness of preprocedural soluble CD40 ligand for predicting restenosis after percutaneous coronary intervention in patients with stable coronary artery disease. Am J Cardiol. 2006;97:198-202. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.